Abstract: The present invention provides new GABAA receptor-binding compounds that modify the activation of GABAA, their use in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.

Abstract: The present invention provides new GABAA receptor-binding compounds that modify the activation of GABAA, their use in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.

Abstract: A group of peptides is provided which activate or inhibit toll-like receptor 4 (TLR4) and may be used to modulate inflammatory signaling and host defense pathways. The peptides were derived in silico and tested in vitro in cell cultures. These peptides may be used in the preparation of immunomodulatory compositions such as vaccine adjuvants and in pharmaceutical compositions for immunomodulation of the innate immune system such as vaccine adjuvants. The peptides may also be used in the preparation of TLR4 activators, TLR4 inhibitors and MD2 labels, e.g., for research purposes.

Abstract: The present invention provides pesticidal compositions comprising an agriculturally acceptable carrier and at least one compound of Formula (A) or a salt thereof as described herein. The present invention also provides methods for the control or prevention of pest in a crop field, comprising applying the compound(s) of Formula (A) or pesticidal compositions thereof to the pest, a locus of the pest and/or an area in which pest infestation is to be prevented so as to thereby control or prevent pest in the crop field.

Abstract: The present invention relates to a GABAA receptor-binding peptide comprising an amino acid sequence X1-X2-X3-X4-X5, wherein the amino acid residue X1 is histidine, arginine, threonine, L-cyclohexyl-alanine, 2-flouro-L-phenylalanine or 3-methyl-L-histidine; X2 is threonine, N-methyl-threonine, proline, leucine, isoleucine or phenylalanine; X3 is tryptophan, N-methyl-tryptophan, serine, threonine or proline; X4 is glutamine, proline, lysine, tyrosine, alanine, glycine or absent; and X5 is lysine, glutamic acid, aspartic acid, threonine, alanine, glycine or absent. In particular, the GABAA receptor-binding peptides of the present invention have amino acid sequences selected from SEQ ID NOs: 1 to 15. These peptides were tested and validated using electrophysiological recordings on the human GABAA receptor comprising of the following subunits ?1?3?2 and used in the preparation of a neuroactive pharmaceutical composition, in improving sperm motility or in labeling of biomolecules.

Abstract: A group of peptides is provided which activate or inhibit toll-like receptor 4 (TLR4) and may be used to modulate inflammatory signaling and host defense pathways. The peptides were derived in silico and tested in vitro in cell cultures. These peptides may be used in the preparation of immunomodulatory compositions such as vaccine adjuvants and in pharmaceutical compositions for immunomodulation of the innate immune system such as vaccine adjuvants. The peptides may also be used in the preparation of TLR4 activators, TLR4 inhibitors and MD2 labels, e.g., for research purposes.

Abstract: The present invention discloses a peptide capable of stabilizing mutation-induced GBE1 protein destabilization, conjugates comprising same and uses thereof for the treatment of diseases and disorders associate with glycogen storage.